Dendritic cell-derived exosome (DEX) therapy for digestive system cancers: Recent advances and future prospect
- 6 April 2024
- journal article
- review article
- Published by Elsevier in Pathology - Research and Practice
- Vol. 257, 155288
Abstract
No abstract availableKeywords
Funding Information
- Deanship of Scientific Research, King Saud University
- King Khalid University (1/226/44)
This publication has 67 references indexed in Scilit:
- Combination therapy with dendritic cell loaded-exosomes supplemented with PD-1 inhibition at different time points have superior antitumor effect in hepatocellular carcinomaCancer Immunology, Immunotherapy, 2023
- Tumor-targeted exosomes for delivery of anticancer drugsCancer Letters, 2023
- Exosomes based strategies for brain drug deliveryBiomaterials, 2022
- Cellular nanovesicles for therapeutic immunomodulation: A perspective on engineering strategies and new advancesActa Pharmaceutica Sinica B, 2022
- Exosome detection via surface-enhanced Raman spectroscopy for cancer diagnosisActa Biomaterialia, 2022
- Engineered exosome-like nanovesicles suppress tumor growth by reprogramming tumor microenvironment and promoting tumor ferroptosisActa Biomaterialia, 2021
- Membrane-anchored heat-shock protein 70 (Hsp70) in cancerCancer Letters, 2020
- Current knowledge on exosome biogenesis and releaseCellular and Molecular Life Sciences, 2017
- Pancreatic cancer derived exosomes regulate the expression of TLR4 in dendritic cells via miR-203Cellular Immunology, 2014
- Mature dendritic cells secrete exosomes with strong ability to induce antigen-specific effector immune responsesBlood Cells, Molecules, and Diseases, 2005